Compile Data Set for Download or QSAR
maximum 50k data
Found 168 Enz. Inhib. hit(s) with Target = 'Mitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085]'
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415402(Intermediate 1-1-2 | US10428063, Example 2)
Affinity DataIC50:  7.89nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415417(Intermediate 1-2-9 | US10428063, Example 17)
Affinity DataIC50:  8.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415431(2-[3-(2-methoxyethoxy)pyridin-4-yl]-5-methyl-3-(ph...)
Affinity DataIC50:  9.93nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415406(Intermediate 1-1-3 | US10428063, Example 6)
Affinity DataIC50:  10.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415418(Example 18 (2-(3-fluoropyridin-4-yl)-3-(phenylamin...)
Affinity DataIC50:  11.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415401(Intermediate 1-1-1 (4-hydroxy-6,6-dimethyl-2-oxo-N...)
Affinity DataIC50:  11.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415420(Intermediate 1-1-5 | US10428063, Example 20)
Affinity DataIC50:  13.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415404(Example 4 (1-ethyl-6,6-dimethyl-3-(phenylamino)-2-...)
Affinity DataIC50:  14.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415424(N-{4-[5-methyl-4-oxo-3-(phenylamino)-4,5,6,7-tetra...)
Affinity DataIC50:  15.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415412(Intermediate 1-2-7 | US10428063, Example 12)
Affinity DataIC50:  15.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415425(US10428063, Example 25 | US10428063, Example 40 | ...)
Affinity DataIC50:  17.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415414(Example 14 (N-{4-[4-oxo-3-(phenylamino)-4,5,6,7-te...)
Affinity DataIC50:  18.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415416(Intermediate 1-2-8 | US10428063, Example 16)
Affinity DataIC50:  19.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415447(3-[(3-fluorophenyl)amino]-2-[3-(2-methoxyethoxy)py...)
Affinity DataIC50:  19.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415419(Example 19 (1-ethyl-3-{4-[4-oxo-3-(phenylamino)-4,...)
Affinity DataIC50:  19.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415407(Intermediate 1-1-4 | US10428063, Example 7)
Affinity DataIC50:  19.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415427(2-[3-(cyclopropylmethoxy)pyridin-4-yl]-5-methyl-3-...)
Affinity DataIC50:  21.7nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415434(5-methyl-3-(phenylamino)-2-{3-[(3S)-tetrahydrofura...)
Affinity DataIC50:  22.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415423(N-{4-[5-methyl-4-oxo-3-(phenylamino)-4,5,6,7-tetra...)
Affinity DataIC50:  23.2nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415439(2-[3-(cyclopropylmethoxy)pyridin-4-yl]-3-[(3-fluor...)
Affinity DataIC50:  24.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415422(2-(3-methoxypyridin-4-yl)-5-methyl-3-(phenylamino)...)
Affinity DataIC50:  26.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415445(3-[(3,4-difluorophenyl)amino]-2-[3-(2-methoxyethox...)
Affinity DataIC50:  28nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415425(US10428063, Example 25 | US10428063, Example 40 | ...)
Affinity DataIC50:  28.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415446(3-[(4-fluorophenyl)amino]-2-[3-(2-methoxyethoxy)py...)
Affinity DataIC50:  32.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415436(2-(3H-imidazo[4,5-b]pyridin-7-yl)-5-methyl-3-(phen...)
Affinity DataIC50:  34.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415405(Example 5 (1-ethyl-3-(phenylamino)-2-(pyridin-4-yl...)
Affinity DataIC50:  35.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415441(2-[3-(2,2-difluoroethoxy)pyridin-4-yl]-3-[(3-fluor...)
Affinity DataIC50:  36.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415432(2-[3-(benzyloxy)pyridin-4-yl]-5-methyl-3-(phenylam...)
Affinity DataIC50:  41.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415426(2-[3-(2-hydroxyethoxy)pyridin-4-yl]-5-methyl-3-(ph...)
Affinity DataIC50:  47.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415428(5-methyl-3-(phenylamino)-2-(3-propoxypyridin-4-yl)...)
Affinity DataIC50:  51.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415433(5-methyl-3-(phenylamino)-2-[3-(3,3,3-trifluoroprop...)
Affinity DataIC50:  51.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415438(2-[3-(cyclopropylmethoxy)pyridin-4-yl]-3-[(4-fluor...)
Affinity DataIC50:  56.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415437(2-[3-(cyclopropylmethoxy)pyridin-4-yl]-3-[(3,4-dif...)
Affinity DataIC50:  59.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415411(Example 11 (1-ethyl-3-[(4-fluorophenyl)amino]-2-(p...)
Affinity DataIC50:  64.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415444(2-{3-[2-(dimethylamino)ethoxy]pyridin-4-yl}-3-[(4-...)
Affinity DataIC50:  69.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415429(2-[3-(2,2-difluoroethoxy)pyridin-4-yl]-5-methyl-3-...)
Affinity DataIC50:  70.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415415(Example 15 (N-{4-[1-ethyl-4-oxo-3-(phenylamino)-4,...)
Affinity DataIC50:  79nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415430(5-methyl-3-(phenylamino)-2-[3-(2,2,2-trifluoroetho...)
Affinity DataIC50:  84.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415435(2-[3-(3,3-dimethylbutoxy)pyridin-4-yl]-5-methyl-3-...)
Affinity DataIC50:  85.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415442(2-[3-(2,2-difluoroethoxy)pyridin-4-yl]-3-[(4-fluor...)
Affinity DataIC50:  111nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415443(2-[3-(2,2-difluoroethoxy)pyridin-4-yl]-3-[(3,4-dif...)
Affinity DataIC50:  136nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415408(Intermediate 1-2-6 | US10428063, Example 8)
Affinity DataIC50:  138nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415421(Intermediate 1-2-11 | US10428063, Example 21)
Affinity DataIC50:  170nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM162190(US9682995, 89)
Affinity DataIC50:  210nMpH: 8.0Assay Description:Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose aff...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415403(Intermediate 1-2-3 | US10428063, Example 3)
Affinity DataIC50:  244nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415410((2-methyl-N-{4-[5-(2-methylpropanoyl)-4-oxo-3-(phe...)
Affinity DataIC50:  319nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415409(Example 9 (1-(2-methoxyethyl)-3-(phenylamino)-2-(p...)
Affinity DataIC50:  354nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415413(Example 13 (1-ethyl-2-(2-methylpyridin-4-yl)-3-(ph...)
Affinity DataIC50:  972nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM162171(US9682995, 70)
Affinity DataIC50:  1.70E+3nMpH: 8.0Assay Description:Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose aff...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM162106(US9682995, 24)
Affinity DataIC50:  3.10E+3nMpH: 8.0Assay Description:Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose aff...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 168 total ) | Next | Last >>
Jump to: